Moreover, the panelists emphasized that real-world evidence goes beyond clinical trial data. It involves continuous patient ...

The FDA has taken the unusual step of over-ruling its own advisory committee and approving Karyopharm’s Xpovio as a last-line therapy for multiple myeloma. In February, the US regulator’s ...

NICE has defended a trio of decisions on new therapies for multiple myeloma, which saw two drugs approved for restricted use in England and Wales and a third turned down altogether. The recent ...

Testing that can help with the early detection and treatment of diseases including cancer, Alzheimer’s and multiple sclerosis will be accessible to more patients soon. Right now, health insurance ...

leading to more than 12,000 deaths in the U.S. It has previously been approved for multiple myeloma patients who have received at least four prior lines of therapy. In March, an FDA expert panel ...